Abstract
Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Volume: 12 Issue: 4
Author(s): Zahra Shaghaghi and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Abstract: Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Export Options
About this article
Cite this article as:
Shaghaghi Zahra and Hosseinimehr Jalal Seyed*, Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (4) . https://dx.doi.org/10.2174/1574892812666170829150057
DOI https://dx.doi.org/10.2174/1574892812666170829150057 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Phytoestrogens: Pharmacological and Therapeutic Perspectives
Current Drug Targets Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry The Antinflammatory Effect of Alpha-MSH in Skin: A Promise for New Treatment Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural Cyclic Peptides as Clinical and Future Therapeutics
Current Organic Chemistry Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets Porphyrin-Carbohydrate Conjugates: Impact of Carbohydrate Moieties in Photodynamic Therapy (PDT)
Anti-Cancer Agents in Medicinal Chemistry Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin
Current Pharmaceutical Biotechnology Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design